Immunotherapy agent promising in NSCLC
GENEVA-Patients with NSCLC who received MAGE-A3 ASCI (antigen-specific cancer immunotherapeutic) had longer disease-free (HR 0.76) and overall survival (HR 0.81) than those who received placebo, although in this phase II study of 182 patients, the difference did not reach significance.
GENEVA-Patients with NSCLC who received MAGE-A3 ASCI (antigen-specific cancer immunotherapeutic) had longer disease-free (HR 0.76) and overall survival (HR 0.81) than those who received placebo, although in this phase II study of 182 patients, the difference did not reach significance. Johan Vansteenkiste, MD, PhD, of University Hospital Gasthuisberg, Belgium, reported the results, with 44 months of follow-up, at the 1st European Lung Cancer Conference (abstract 1480). An efficacy phase III study (MAGRIT) is ongoing.
Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System
Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.
